TEVA PHARMACEUTICAL INDUSTRIES LTD Revenue From Contract With Customer Excluding Assessed Tax

• TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +4.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
• This data is from TEVA PHARMACEUTICAL INDUSTRIES LTD's annual report (Form 10-K), filed with the SEC on February 3, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $5.65 billion | Q2 2017: $5.72 billion | Q3 2017: $5.62 billion | Q4 2017: $5.40 billion | Q1 2018: $4.92 billion | Q2 2018: $4.55 billion | Q3 2018: $4.39 billion | Q4 2018: $4.42 billion | Q1 2019: $4.15 billion | Q2 2019: $4.18 billion | Q3 2019: $4.09 billion | Q4 2019: $4.47 billion | Q1 2020: $4.36 billion | Q2 2020: $3.87 billion | Q3 2020: $3.98 billion | Q4 2020: $4.45 billion | Q1 2021: $3.98 billion | Q2 2021: $3.91 billion | Q3 2021: $3.89 billion | Q1 2022: $3.66 billion | Q2 2022: $3.79 billion | Q3 2022: $3.60 billion | Q1 2023: $3.66 billion | Q2 2023: $3.88 billion | Q3 2023: $3.85 billion | Q1 2024: $3.82 billion | Q2 2024: $4.16 billion | Q3 2024: $4.33 billion | Q1 2025: $3.89 billion | Q2 2025: $4.18 billion | Q3 2025: $4.48 billion.
• Over the full 10 years of available data (2016 to 2025), TEVA PHARMACEUTICAL INDUSTRIES LTD's Revenue From Contract With Customer Excluding Assessed Tax has declined by 21.2%.
• Historical annual values: Fiscal year 2025: $17.26 billion | Fiscal year 2024: $16.54 billion | Fiscal year 2023: $15.85 billion | Fiscal year 2022: $14.93 billion | Fiscal year 2021: $15.88 billion | Fiscal year 2020: $16.66 billion | Fiscal year 2019: $16.89 billion | Fiscal year 2018: $18.27 billion | Fiscal year 2017: $21.85 billion | Fiscal year 2016: $21.90 billion.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026